Clinical Report: AI-Designed Binder Improves CAR T Cell Activity in Mice

Overview

An AI-designed protein binder enhanced CAR T cell efficacy against tumors in a mouse model of multiple myeloma, outperforming traditional antibody-derived binders.

Background

Chimeric antigen receptor (CAR) T cell therapy has shown promise in treating B-cell malignancies, particularly multiple myeloma. Current therapies utilize antibody-derived binders, which may have limitations in efficacy and specificity. The exploration of AI-designed binders represents a novel approach.

Data Highlights

The study generated and screened 1,758 de novo binders against BCMA, CD19, and CD22, identifying key issues such as tonic signaling and off-target activity. One binder, B5, demonstrated effective tumor control in mice, outperforming existing therapies.

Key Findings

• AI-designed binders were developed from scratch, offering potential advantages over traditional antibody-derived binders.
• Three main issues were identified: tonic signaling, inaccessible binding sites, and off-target activity.
• Binder B5 showed antigen-dependent activation and cytokine release in primary CAR T cells.
• The optimized variant B5.I0 controlled tumor growth more effectively than approved BCMA-targeting CAR T therapies.
• Modifications to binders targeting CD22 reduced off-target activation while maintaining on-target activity.
• The CD19 program faced challenges due to obstruction by CD81, limiting effective binding.

Clinical Implications

The findings indicate that AI-designed binders could enhance the specificity and efficacy of CAR T cell therapies.

Conclusion

This study demonstrates the potential of AI in designing more effective CAR T cell therapies.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. the medicine maker, 2026 -- CRISPR Enables In Vivo CAR T Cell Production
3. Frontiers in Immunology, 2026 -- Engineering a juxtamembrane-targeting CAR T-cell against mesothelin
4. the medicine maker, 2026 -- AI Framework Helps Identify New CAR T Target
5. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1 | Journal of Clinical Oncology
6. Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.
7. CARVYKTI | FDA
8. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4)
9. Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1 | Journal of Clinical Oncology
10. Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology.
11. April 5, 2024 Clinical Review and Evaluation - CARVYKTI
12. BCMA-directed CAR-T cell therapy in relapsed/refractory multiple myeloma: efficacy, safety, survival, and future directions – A systematic review and meta-analysis - ScienceDirect
13. FDA approves labeling changes that include a Boxed Warning for Immune Effector Cell-associated Enterocolitis following treatment with Ciltacabtagene Autoleucel (CARVYKTI, Janssen Biotech, Inc.) | FDA
14. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis
15. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study - PubMed